查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018846

感染疾病疫苗市场：2026-2032年全球市场预测（依疫苗类型、给药途径、最终用户和通路划分）

Infectious Vaccines Market by Vaccine Type, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年感染疾病疫苗市值为348.8亿美元，预计到2026年将成长至382.3亿美元，复合年增长率为9.76%，到2032年将达到669.8亿美元。

主要市场统计数据
基准年 2025 348.8亿美元
预计年份：2026年 382.3亿美元
预测年份 2032 669.8亿美元
复合年增长率 (%) 9.76%

简单介绍科学进步和营运演变如何改变感染疾病疫苗的研发过程和供应模式。

在科学创新、公共卫生重点转变和不断发展的操作实践的推动下，感染疾病疫苗领域正在经历一场变革。在过去十年间，mRNA和病毒载体等平台技术的进步已从实验方法发展成为临床验证的工具，并在整体的预防和治疗领域引起了广泛关注。同时，结合疫苗、灭活疫苗、减毒疫苗、次单元和类毒素疫苗等现有方法也透过製剂改进、联合策略和标靶抗原设计不断发展。

本文探讨了技术、监管和分销变革如何共同推动疫苗研发和部署实践的快速发展。

感染疾病疫苗的格局正在重塑，这不仅得益于科学突破，也得益于一系列相互交织的变革，这些变革影响着监管预期、供应链网络和医疗服务模式。首先，平台多样化正在加速。传讯RNA（mRNA）技术和病毒载体正从概念验证（PoC）阶段迈向大规模生产，而自扩增RNA（saRNA）和改良的脂质体配方则正在拓展其适用范围。成熟的平台，例如结合疫苗、不活化疫苗和类毒素疫苗，也并未停滞不前。它们正受益于抗原工程（可增强免疫抗原性和持久性）、佐剂优化以及新的给药形式。

对 2025 年关税措施将如何重塑疫苗生产和分销的供应链、筹资策略和采购趋势进行现实评估。

2025年起实施的关税将影响疫苗原料、组件及相关耗材，为生产商、经销商和采购机构带来了新的营运挑战。关税政策影响整个价值链的单位成本结构，促使生产商重新评估其全球筹资策略，尽可能优先考虑本地生产，并加快供应商选择流程以增强供应韧性。同时，采购机构和公共卫生采购负责人也积极应对，审查供应商多元化策略，并更加重视合约保障措施，以降低供应中断的风险。

详细的細項分析揭示了疫苗平台选择、给药途径、最终用户环境和分销管道如何相互作用并影响部署结果。

细分市场层面的趋势反映出疫苗类型、给药途径、最终用户和分销管道之间存在显着差异，因此了解这些差异对于策略优先排序至关重要。无论疫苗类型如何，结合疫苗（例如Hib结合疫苗、脑膜炎双球菌结合疫苗和肺炎球菌结合疫苗）在儿童和高风险成人免疫计划中仍然至关重要，因为这些计划优先考虑长期免疫抗原性和群体免疫。灭活疫苗（包括甲型肝炎疫苗、流感疫苗、脊髓灰质炎疫苗和狂犬病疫苗）由于其已确立的安全性以及广泛的监管认可，仍被广泛使用。减毒活病毒疫苗减毒活病毒疫苗（例如流感疫苗、麻疹脊髓灰质炎、口服小儿麻痹疫苗、德国德国麻疹和水痘疫苗）可提供强大的免疫反应，并在大规模免疫宣传活动中发挥核心作用，但需要小心处理和低温运输管理。 mRNA技术（分为脂质奈米颗粒mRNA和自扩增mRNA）由于其开发速度快和抗原设计柔软性，正在迅速扩展到新的适应症。次单元疫苗，例如蛋白质次单元和类病毒颗粒（VLPs），具有更高的安全性和生产便利性。同时，针对白喉、百日咳和破伤风的类毒素疫苗仍然是许多疫苗接种计画的支柱。腺病毒、MVA 和 VSV 等病毒载体因其能够诱导强大的细胞免疫，在疾病预防和治疗中仍被广泛应用。

解释美洲、欧洲、中东和非洲以及亚太地区不同的医疗保健基础设施和法规环境如何影响疫苗策略的关键区域因素。

区域趋势对产品设计、监管策略、製造地和部署重点都有显着影响。在美洲，完善的免疫接种计划和发达的公立及私立医疗卫生基础设施为医院药房、广泛的零售药房和线上药房网络等先进分销渠道提供了支持，同时也为下一代平台和成人免疫接种倡议提供了沃土。因此，开发人员通常会优先考虑符合监管要求和与支付方合作的策略，这些策略既体现了民营市场机制，也体现了大规模公共卫生采购流程。

从策略角度概述公司和合作伙伴如何调整其平台投资、製造能力和协作生态系统，以确保竞争优势。

生物製药、生物技术和契约製造领域的领先企业正透过平台投资、策略联盟和扩大产能来重新定义其竞争地位。一些研发公司专注于平台扩充性，这意味着它们正在建构将mRNA、病毒载体或蛋白质次单元平台应用于多种适应症的能力，以最大限度地提高研发效率。合约研发生产机构（CDMO）正在扩展其填充、包装和模组化生产能力，以满足对传统疫苗和新型疫苗的需求，同时专注于低温运输创新和一次性使用技术。

透过结合平台柔软性、製造韧性和有针对性的商业性参与，为加速采用和降低营运风险提供切实可行的建议。

产业领导者应采取多管齐下的策略，平衡技术创新、业务永续营运和市场驱动的部署。优先考虑平台柔软性，使企业能够灵活地将研发资源分配到不同适应症，并快速应对新出现的病原体威胁。同时，投资于製造韧性，例如本地化生产、多元化的供应商网路以及模组化的填充和包装能力，可以降低因关税等外部衝击和成本波动带来的风险。领导者也应重视给药途径的创新，这些创新可以降低物流复杂性、提高病患接受度，或在当地社区推广无针给药方案。

对用于评估整个疫苗计划的平台性能、供应链风险和相关人员细分的调查来源和分析方法进行透明的总结。

本研究整合了公开的科学文献、监管指导文件、产业技术报告以及对研发、生产、法规遵循和采购领域专家的结构化访谈。透过与疫苗研发负责人、契约製造组织 (CMO)、供应链专家和公共卫生采购负责人的讨论，收集了关键的定性数据，以了解实际情况和策略重点。辅助研究包括同行评审期刊、监管公告和技术白皮书，重点关注平台技术、给药途径和分销创新。

一项权威的综合分析强调了整合科学、製造和商业策略的必要性，以将技术进步转化为实际的公共卫生成果。

感染疾病疫苗正处于科学、政策和物流快速发展的十字路口，其成功取决于技术能力与切实可行的供应策略的整合。从结合疫苗和灭活疫苗到mRNA疫苗、病毒载体疫苗、次单位疫苗和类毒素疫苗，多种平台为满足未被满足的需求提供了多种途径。同时，给药途径的创新为提高人群保护水准和简化疫苗部署提供了可能。然而，这些科学机会必须与低温运输限制、采购机制和监管环境等现实因素平衡。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：感染疾病疫苗市场：依疫苗类型划分

  • 组合型
    • Hib 组合型
    • 脑膜炎双球菌结合物
    • 肺炎链球菌结合物
  • 失活
    • 甲型肝炎
    • 流感
    • 脊髓灰质炎
    • 狂犬病
  • 活病毒疫苗
    • 流感（活病毒疫苗）
    • 麻疹
    • 口服脊髓灰质炎
    • 德国麻疹
    • 水痘
  • mRNA
    • 脂质奈米颗粒mRNA
    • 自扩增mRNA
  • 次单元
    • 蛋白质次单元
    • 类病毒颗粒
  • 类毒素
    • 白喉
    • 百日咳
    • 破伤风
  • 病毒载体
    • 腺病毒
    • MVA
    • VSV

第九章：感染疾病疫苗市场：依给药途径划分

  • 皮内注射
  • 肌肉内部
  • 鼻内
  • 口服
  • 皮下

第十章：感染疾病疫苗市场：依最终用户划分

  • 诊所
    • 一般医疗
    • 专业
  • 医院
    • 私人的
    • 一般的
  • 药局
    • 在线的
    • 零售
  • 公共卫生中心
    • 地区
    • 都市区

第十一章：感染疾病疫苗市场：依分销管道划分

  • 政府机构
    • 地区
    • 国内的
  • 医院药房
    • 在医院里
    • 门诊
  • 网路药房
    • 直销
    • 平台
  • 零售药房
    • 链
    • 独立的

第十二章：感染疾病疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：感染疾病疫苗市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：感染疾病疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国感染疾病疫苗市场

第十六章：中国感染疾病疫苗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adimmune Corporation
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E Limited
  • BioNTech SE
  • CanSino Biologics
  • China National Biotechnology Group
  • CSL Limited
  • Dynavax Technologies
  • Emergent BioSolutions, Inc.
  • Genocea Biosciences
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Microgen
  • Mitsubishi Tanabe Pharma
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India
  • Sinovac Biotech Ltd.
  • Valneva SE
  • Vaxcyte, Inc.
  • VBI Vaccines, Inc.
Product Code: MRR-ED54C46E8F6D

The Infectious Vaccines Market was valued at USD 34.88 billion in 2025 and is projected to grow to USD 38.23 billion in 2026, with a CAGR of 9.76%, reaching USD 66.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.88 billion
Estimated Year [2026] USD 38.23 billion
Forecast Year [2032] USD 66.98 billion
CAGR (%) 9.76%

A concise introduction outlining how scientific advances and operational evolution are reshaping infectious vaccine development pathways and delivery models

The infectious vaccines landscape is undergoing a transformative phase driven by scientific innovation, evolving public health priorities, and shifting operational practices. Over the last decade, advances in platform technologies such as mRNA and viral vectors have matured from experimental modalities into clinically validated tools, prompting broader interest across preventive and therapeutic indications. Concurrently, established modalities including conjugate, inactivated, live attenuated, subunit, and toxoid vaccines continue to evolve through formulation improvements, combination strategies, and targeted antigen design.

Emerging manufacturing techniques, improved cold chain management, and digital supply chain visibility are enabling more reliable distribution across diverse healthcare settings. Regulatory pathways are adapting to accommodate novel platforms while maintaining rigorous safety and efficacy standards, and public health programs are increasingly prioritizing broader vaccine access and adult immunization strategies. As a result, stakeholders from biopharma developers to public immunization programs are recalibrating product development, partnership, and deployment plans to reflect both technological promise and operational realities.

This introduction frames the report's focus on platform diversity, route-of-administration innovation, end-user dynamics across clinics, hospitals, pharmacies, and public health centers, and the distribution mechanisms that will shape uptake and impact. It sets the scene for detailed analysis that follows, identifying where scientific opportunity intersects with commercial and public health imperatives.

An exploration of converging technological, regulatory, and distributional shifts that are driving rapid evolution in vaccine development and deployment practices

The landscape for infectious vaccines is being reshaped by a set of converging shifts that extend beyond scientific breakthroughs to influence regulatory expectations, supply networks, and care delivery models. First, platform diversification is accelerating: messenger RNA technologies and viral vectors have moved from proof-of-concept to scalable manufacturing, while self-amplifying RNA and refined lipid nanoparticle formulations are increasing the range of feasible indications. Established platforms such as conjugate, inactivated, and toxoid vaccines are not standing still; they are benefitting from antigen engineering, adjuvant optimization, and novel presentation formats that improve immunogenicity and durability.

Second, administration routes are expanding in importance. Intramuscular delivery remains dominant for many programs, yet intradermal, intranasal, oral, and subcutaneous options are attracting renewed attention because they can improve patient acceptance, simplify logistics, or confer mucosal immunity. Third, end-user segmentation is influencing distribution strategies: clinics, hospitals, pharmacies, and public health centers each present distinct operational constraints and opportunities, shaping packaging, cold chain requirements, and digital record integration. Fourth, distribution channels are fragmenting and specializing, with government procurement, hospital pharmacies, online pharmacies, and retail outlets each requiring tailored commercial approaches.

Together, these shifts create a dynamic environment where agility in development and distribution, coupled with strategic partnerships and regulatory foresight, will determine which programs achieve broad and sustained adoption.

A pragmatic assessment of how 2025 tariff measures are reshaping supply chains, sourcing strategies, and procurement dynamics across vaccine manufacturing and distribution

The introduction of tariffs affecting vaccine inputs, components, and related consumables in 2025 has introduced a new operational variable for manufacturers, distributors, and procurement agencies. Tariff policies influence unit cost structures across the value chain, driving manufacturers to re-evaluate global sourcing strategies, prioritize localized production where feasible, and accelerate supplier qualification processes to maintain resilience. In parallel, procurement organizations and public health purchasers have responded by reassessing supplier diversification and by placing greater emphasis on contractual safeguards to mitigate supply disruptions.

Tariffs also affect the economics of distribution channels. Hospital pharmacies, retail and online pharmacies, and government procurement entities must integrate additional cost and compliance considerations into purchasing decisions, which can alter relative attractiveness of imported versus domestically produced products. For clinical developers, the cumulative cost effects have incentivized consideration of regional manufacturing partnerships and technology transfer agreements to reduce exposure to tariff-related volatility.

From a downstream perspective, routes of administration that reduce reliance on specialized cold chain components or disposable delivery devices may gain pragmatic appeal because they can lower the exposure to tariff-driven cost increases for ancillary supplies. Overall, the tariff landscape in 2025 underscores the importance of supply chain transparency, contractual flexibility, and proactive engagement with procurement bodies to preserve access while protecting margins and continuity of supply.

In-depth segmentation insights revealing how vaccine platform choices, administration routes, end-user settings, and distribution channels interact to shape adoption outcomes

Segment-level dynamics reflect pronounced heterogeneity across vaccine types, administration routes, end users, and distribution channels, and understanding these distinctions is essential for strategic prioritization. Across vaccine types, conjugate approaches-spanning Hib conjugate, meningococcal conjugate, and pneumococcal conjugate formats-remain essential for pediatric and high-risk adult programs where long-term immunogenicity and herd protection are priorities. Inactivated platforms, including hepatitis A, influenza, polio, and rabies formulations, continue to be widely used due to established safety profiles and broad regulatory familiarity. Live attenuated vaccines such as influenza live formulations, measles, oral polio, rubella, and varicella offer potent immune responses and are central to mass immunization campaigns but require careful handling and cold chain management. mRNA technologies, differentiated into lipid nanoparticle mRNA and self-amplifying mRNA, are rapidly expanding into new indications because of their development speed and antigen design flexibility. Subunit approaches, including protein subunit and virus-like particle constructs, provide attractive safety and manufacturability attributes, while toxoid vaccines targeting diphtheria, pertussis, and tetanus remain pillars of many immunization schedules. Viral vectors such as adenovirus, MVA, and VSV continue to be leveraged for their ability to elicit strong cellular immunity in both prophylactic and therapeutic contexts.

When considering routes of administration, intradermal, intramuscular, intranasal, oral, and subcutaneous options create differing operational demands and patient experiences that influence adoption in clinics, hospitals, pharmacies, and public health centers. End-user settings vary widely: clinics encompassing general practice and specialty care have different throughput and storage needs compared with hospitals, where private and public institutions have distinct procurement and formulary processes; pharmacies operate across online and retail formats with unique customer interfaces; and public health centers in rural and urban settings confront divergent logistical constraints. Distribution channels-government agencies divided into local and national tiers, hospital pharmacies operating in-hospital and outpatient services, online pharmacies delivering direct and platform-mediated sales, and retail pharmacies split between chain and independent models-further shape commercial approaches. These segmentation dimensions interact; for example, a protein subunit vaccine delivered intramuscularly for adult use may follow a distinct distribution and procurement path than an intranasal live attenuated pediatric vaccine procured through national public health tenders.

Recognizing these interdependencies enables stakeholders to align development, manufacturing, and commercialization strategies with the specific requirements of target segments, reducing time to adoption and enhancing operational fit.

Key regional considerations explaining how distinct healthcare infrastructures and regulatory environments in the Americas, EMEA, and Asia-Pacific shape vaccine strategy

Regional dynamics exert a strong influence on product design, regulatory strategy, manufacturing footprint, and deployment priorities. In the Americas, established immunization programs and well-developed private and public healthcare infrastructures support advanced distribution channels such as hospital pharmacies and extensive retail and online pharmacy networks, while also providing fertile ground for next-generation platforms and adult immunization initiatives. Consequently, developers often prioritize regulatory alignment and payer engagement strategies that reflect both private market mechanisms and large-scale public health procurement processes.

Europe, Middle East & Africa present a mosaic of regulatory frameworks, public health priorities, and supply chain capabilities. In parts of Europe, sophisticated regulatory pathways and manufacturing clusters allow for rapid adoption of novel platforms, whereas regions across the Middle East and Africa may prioritize thermostable formulations, simplified administration routes, and partnership models that support local capacity building to address access constraints. Public health centers in rural and urban areas across this region demand flexible cold chain solutions and deployment strategies that can operate under variable infrastructure conditions.

Asia-Pacific encompasses a wide spectrum from advanced manufacturing hubs to rapidly developing public health systems. Countries with strong biotech ecosystems are investing heavily in mRNA, viral vector, and next-generation manufacturing capabilities, while others focus on broadening routine immunization with established conjugate, inactivated, and toxoid vaccines. Across the region, there is heightened interest in technologies and distribution models that reduce supply chain vulnerability, enable local production, and support rapid scale-up during outbreaks. Taken together, regional priorities influence product specifications, regulatory timelines, and supply chain investments, making geographic strategy a central component of any vaccine program.

A strategic synthesis of how companies and partners are aligning platform investments, manufacturing capabilities, and collaborative ecosystems to secure competitive advantage

Leading organizations across biopharma, biotech, and contract manufacturing are redefining competitive positioning through combinations of platform investment, strategic alliances, and capacity expansion. Some developers are focusing on platform extensibility, meaning they are building capabilities to repurpose mRNA, viral vector, or protein subunit platforms for multiple indications to maximize development efficiency. Contract development and manufacturing organizations are expanding fill-finish and modular production capabilities to meet demand for both traditional and novel vaccine formats, with attention to cold chain innovations and single-use technologies.

Collaborative ecosystems are increasingly central: alliances between large pharmaceutical companies, regional manufacturers, and technology specialists facilitate technology transfer, local production, and regulatory navigation. In parallel, specialized suppliers of lipid nanoparticles, adjuvants, and analytical services are gaining importance as strategic partners because they provide critical inputs that affect product performance and manufacturability. Clinical and regulatory consultancies that can support accelerated clinical pathways and dossier preparation across diverse jurisdictions are also valued partners.

Finally, surveillance and real-world evidence providers that integrate immunization registries, adverse event monitoring, and epidemiological data are becoming strategic assets for companies seeking to demonstrate value, optimize post-approval programs, and support targeted vaccination campaigns. Collectively, these trends underscore the need for a coordinated approach to partnerships, capacity planning, and technology investment to maintain competitiveness in a complex and fast-evolving landscape.

Actionable recommendations that combine platform flexibility, manufacturing resilience, and targeted commercial engagement to enhance adoption and mitigate operational risk

Industry leaders should adopt a multi-dimensional strategy that balances technological innovation, operational resilience, and market-tailored deployment. Prioritizing platform flexibility enables organizations to pivot development resources across indications and respond quickly to emerging pathogen threats. At the same time, investing in manufacturing resilience - including localized production, diversified supplier networks, and modular fill-finish capacity - reduces exposure to external shocks and tariff-driven cost variability. Leaders should also evaluate route-of-administration innovations that can lower logistics complexity, improve patient acceptance, or enable needle-free delivery programs in community settings.

Commercially, aligning distribution strategies with the needs of specific end users and channels will accelerate adoption. For instance, engaging early with hospital formulary committees, retail pharmacy chains, and public health purchasers can clarify storage and packaging requirements and inform pricing and contracting approaches. Regulatory foresight is equally important: proactive dialogue with authorities and investment in harmonized dossier development expedite approvals across multiple jurisdictions. Finally, establishing data partnerships for post-market surveillance and real-world effectiveness monitoring strengthens value demonstrations and supports sustained uptake.

By combining platform versatility, supply chain robustness, targeted commercial engagement, and evidence-generation commitments, industry leaders can position their portfolios to capture clinical and public health opportunities while mitigating operational risks.

A transparent summary of research sources and analytical approaches used to evaluate platform performance, supply chain risks, and stakeholder segmentation across vaccine programs

This research synthesizes public scientific literature, regulatory guidance documents, industry technical reports, and structured interviews with subject-matter experts across development, manufacturing, regulatory affairs, and procurement. Primary qualitative inputs were collected through discussions with leaders in vaccine development, contract manufacturing organizations, supply chain specialists, and public health procurement officers to capture operational realities and strategic priorities. Secondary research encompassed peer-reviewed journals, regulatory agency communications, and technical white papers focused on platform technologies, administration routes, and distribution innovations.

Analysis methodologies included comparative platform assessment, supply chain risk mapping, and stakeholder segmentation to identify critical interdependencies among vaccine types, routes of administration, end-user requirements, and distribution channels. Scenario-based evaluation was applied to assess the operational implications of policy changes such as tariff measures, and to explore strategic responses including localization, supplier diversification, and alternative packaging strategies. Wherever possible, findings were cross-validated across multiple sources to ensure robustness, and expert validation sessions were conducted to refine key insights and practical recommendations.

This approach provides a holistic view of technological potential, operational constraints, and commercial pathways without relying on proprietary market estimates, enabling decision-makers to draw practical conclusions for strategy and investment.

A conclusive synthesis emphasizing the need for integrated scientific, manufacturing, and commercial strategies to convert technology advances into reliable public health impact

Infectious vaccines occupy a rapidly evolving intersection of science, policy, and logistics, where success depends on integrating technological capabilities with pragmatic delivery strategies. Platform diversity-from conjugate and inactivated vaccines to mRNA, viral vectors, subunit constructs, and toxoids-offers multiple pathways to address unmet needs, while administration route innovations open possibilities for improved population-level protection and easier deployment. However, these scientific opportunities must be balanced against operational realities including cold chain constraints, procurement mechanisms, and the regulatory landscape.

The cumulative impact of policy actions, such as the tariff measures introduced in 2025, highlights the need for supply chain transparency and flexible sourcing approaches. Regional differences in infrastructure and regulatory maturity further underscore the importance of tailoring strategies to geographic context. Ultimately, organizations that align platform selection with end-user needs, invest in resilient and scalable manufacturing, and engage proactively with payers and public health stakeholders will be best positioned to translate scientific advances into widespread, sustainable public health impact.

This conclusion emphasizes the imperative for coordinated action across R&D, manufacturing, and commercial functions to realize the potential of next-generation vaccines while ensuring equitable and reliable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Vaccines Market, by Vaccine Type

  • 8.1. Conjugate
    • 8.1.1. Hib Conjugate
    • 8.1.2. Meningococcal Conjugate
    • 8.1.3. Pneumococcal Conjugate
  • 8.2. Inactivated
    • 8.2.1. Hepatitis A
    • 8.2.2. Influenza
    • 8.2.3. Polio
    • 8.2.4. Rabies
  • 8.3. Live Attenuated
    • 8.3.1. Influenza Laiv
    • 8.3.2. Measles
    • 8.3.3. Oral Polio
    • 8.3.4. Rubella
    • 8.3.5. Varicella
  • 8.4. MRNA
    • 8.4.1. Lipid Nanoparticle MRNA
    • 8.4.2. Self-Amplifying MRNA
  • 8.5. Subunit
    • 8.5.1. Protein Subunit
    • 8.5.2. Virus-Like Particle
  • 8.6. Toxoid
    • 8.6.1. Diphtheria
    • 8.6.2. Pertussis
    • 8.6.3. Tetanus
  • 8.7. Viral Vector
    • 8.7.1. Adenovirus
    • 8.7.2. MVA
    • 8.7.3. VSV

9. Infectious Vaccines Market, by Route Of Administration

  • 9.1. Intradermal
  • 9.2. Intramuscular
  • 9.3. Intranasal
  • 9.4. Oral
  • 9.5. Subcutaneous

10. Infectious Vaccines Market, by End User

  • 10.1. Clinics
    • 10.1.1. General Practice
    • 10.1.2. Specialty
  • 10.2. Hospitals
    • 10.2.1. Private
    • 10.2.2. Public
  • 10.3. Pharmacies
    • 10.3.1. Online
    • 10.3.2. Retail
  • 10.4. Public Health Centers
    • 10.4.1. Rural
    • 10.4.2. Urban

11. Infectious Vaccines Market, by Distribution Channel

  • 11.1. Government Agencies
    • 11.1.1. Local
    • 11.1.2. National
  • 11.2. Hospital Pharmacies
    • 11.2.1. In-Hospital
    • 11.2.2. Outpatient
  • 11.3. Online Pharmacies
    • 11.3.1. Direct
    • 11.3.2. Platform
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain
    • 11.4.2. Independent

12. Infectious Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Infectious Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Infectious Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Infectious Vaccines Market

16. China Infectious Vaccines Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adimmune Corporation
  • 17.6. AstraZeneca plc
  • 17.7. Bavarian Nordic
  • 17.8. Bharat Biotech
  • 17.9. Biological E Limited
  • 17.10. BioNTech SE
  • 17.11. CanSino Biologics
  • 17.12. China National Biotechnology Group
  • 17.13. CSL Limited
  • 17.14. Dynavax Technologies
  • 17.15. Emergent BioSolutions, Inc.
  • 17.16. Genocea Biosciences
  • 17.17. GlaxoSmithKline plc
  • 17.18. Haffkine Bio-Pharmaceutical Corporation
  • 17.19. Inovio Pharmaceuticals
  • 17.20. Johnson & Johnson
  • 17.21. Merck & Co., Inc.
  • 17.22. Microgen
  • 17.23. Mitsubishi Tanabe Pharma
  • 17.24. Moderna, Inc.
  • 17.25. Novavax, Inc.
  • 17.26. Pfizer Inc.
  • 17.27. Sanofi S.A.
  • 17.28. Serum Institute of India
  • 17.29. Sinovac Biotech Ltd.
  • 17.30. Valneva SE
  • 17.31. Vaxcyte, Inc.
  • 17.32. VBI Vaccines, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HIB CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL CONJUGATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA LAIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MEASLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL POLIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RUBELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LIPID NANOPARTICLE MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PERTUSSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY MVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY VSV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GENERAL PRACTICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY SPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY URBAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY LOCAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY NATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY IN-HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 296. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 302. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 304. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 306. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 310. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY PUBLIC HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY GOVERNMENT AGENCIES, 2018-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 314. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST INFECTIOUS VACCINES MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 316. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 317. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 319. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 320. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 321. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 322. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 323. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY TOXOID, 2018-2032 (USD MILLION)
  • TABLE 324. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 325. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 328. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 329. AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 330. AFRICA INFECTIOUS VACCI